Abstract
Akt, a downstream effector of phosphatidylinositol 3-kinase (PI3K), has often been implicated in prostate cancer. Studies in prostate tumor cell lines revealed that Akt activation is probably important for the progression of prostate cancer to an androgen-independent state. Investigations of human prostate cancer tissues show that although there is neither Akt gene amplification nor enhanced protein expression in prostate cancer compared to normal tissue, poorly differentiated tumors exhibit increased expression of a phosphorylated (activated) form of Akt compared to normal tissue, prostatic intraepithelial neoplasia (PIN) or well-differentiated prostate cancer. Akt phosphorylation is accompanied by the inactivation of ERK, a member of the mitogen activated protein kinase (MAPK) family. In this article, we postulate that Akt promotes androgen-independent survival of prostate tumor cells by modulating the expression and activation of the androgen receptor (AR).
Keywords: akt, pi3k, androgen receptor, mapk, pten, prostate cancer
Current Drug Metabolism
Title: Akt in Prostate Cancer: Possible Role in Androgen-Independence
Volume: 4 Issue: 6
Author(s): Paramita M. Ghosh, Shazli Malik, Roble Bedolla and Jeffrey I. Kreisberg
Affiliation:
Keywords: akt, pi3k, androgen receptor, mapk, pten, prostate cancer
Abstract: Akt, a downstream effector of phosphatidylinositol 3-kinase (PI3K), has often been implicated in prostate cancer. Studies in prostate tumor cell lines revealed that Akt activation is probably important for the progression of prostate cancer to an androgen-independent state. Investigations of human prostate cancer tissues show that although there is neither Akt gene amplification nor enhanced protein expression in prostate cancer compared to normal tissue, poorly differentiated tumors exhibit increased expression of a phosphorylated (activated) form of Akt compared to normal tissue, prostatic intraepithelial neoplasia (PIN) or well-differentiated prostate cancer. Akt phosphorylation is accompanied by the inactivation of ERK, a member of the mitogen activated protein kinase (MAPK) family. In this article, we postulate that Akt promotes androgen-independent survival of prostate tumor cells by modulating the expression and activation of the androgen receptor (AR).
Export Options
About this article
Cite this article as:
Ghosh M. Paramita, Malik Shazli, Bedolla Roble and Kreisberg I. Jeffrey, Akt in Prostate Cancer: Possible Role in Androgen-Independence, Current Drug Metabolism 2003; 4 (6) . https://dx.doi.org/10.2174/1389200033489226
DOI https://dx.doi.org/10.2174/1389200033489226 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot Topic: New Therapies in Prostate Cancer: Controlling Metastatic Disease and Preventing Oncogenesis (Executive Editor: B.F. Schwartz )]
Current Pharmaceutical Design An Emerging Strategy for Cancer Treatment Targeting Aberrant Glycogen Synthase Kinase 3β
Anti-Cancer Agents in Medicinal Chemistry The Molecular Mechanisms of TRAIL Resistance in Cancer Cells: Help in Designing New Drugs
Current Pharmaceutical Design Lactate Transporters and pH Regulation: Potential Therapeutic Targets in Glioblastomas
Current Cancer Drug Targets Poly(lactide-co-glycolide)-based Micro and Nanoparticles for the Controlled Drug Delivery of Vitamins
Current Nanoscience Adiponectin as a Potential Therapeutic Target for Prostate Cancer
Current Pharmaceutical Design Molecular and Enzymatic Profiles of Mammalian DNA Methyltransferases: Structures and Targets for Drugs
Current Medicinal Chemistry Meet the Editorial Board
Combinatorial Chemistry & High Throughput Screening Biomarkers and Osteosarcoma and IGF
Recent Patents on Biomarkers Screening Neuroprotective Agents Through 4-hydroxynonenal, Ethanol, High Glucose, Homocysteine, Okadaic Acid, Rotenone, and Oxygen-Glucose Deprivation Induced PC12 Injury Models: A Review
Current Psychopharmacology Mechanisms of Enhanced Vasoconstriction in the Mouse Model of Atherosclerosis: the Beneficial Effects of Sildenafil
Current Pharmaceutical Biotechnology Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
Recent Patents on Anti-Cancer Drug Discovery Inhibition of TGF- Signaling for the Treatment of Tumor Metastasis and Fibrotic Diseases
Current Signal Transduction Therapy Transmembrane Phosphatases and Cancer Development, the Role of Protein Tyrosine Phosphatase-kappa (PTPκ) and Protein Tyrosine Phosphatase-mu (PTPμ)
Current Signal Transduction Therapy Targeting the Resistance of Pancreatic Cancer Cells to Nutrient Deprivation: Anti-Austerity Compounds
Current Drug Delivery Anticancer Agents Derived from Natural Cinnamic Acids
Anti-Cancer Agents in Medicinal Chemistry Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Production and Application of Copper Radiopharmaceuticals
Current Radiopharmaceuticals Histone Deacetylase Inhibitors as Potent Modulators of Cellular Contacts
Current Drug Targets Cystine Dimethyl Ester Induces Apoptosis Through Regulation of PKC-δ and PKC-ε in Prostate Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry